TASLY(SH:600535)2025-04-28 09:30Revenue and Profitability - The company's revenue for Q1 2025 was CNY 2,054,886,385.20, a slight increase of 0.30% compared to CNY 2,048,654,962.31 in the same period last year[4] - Net profit attributable to shareholders increased by 6.47% to CNY 314,309,585.08 from CNY 295,211,183.76 year-on-year[4] - Net profit for Q1 2025 was CNY 332,084,620.96, up from CNY 293,013,054.52 in Q1 2024, reflecting a growth of 13.3%[18] - Total comprehensive income attributable to the parent company was CNY 315,495,489.57, an increase from CNY 290,052,754.70 in the previous year, reflecting a growth of approximately 8.7%[20] - The company's gross profit margin improved to approximately 38.5% in Q1 2025, compared to 36.5% in Q1 2024[18] Earnings Per Share - The basic and diluted earnings per share rose by 6.48% to CNY 0.2104 from CNY 0.1976 in the previous year[4] - Basic and diluted earnings per share increased to CNY 0.2104 from CNY 0.1976, representing a rise of about 3.5%[20] Cash Flow - The company reported a net cash flow from operating activities of -CNY 362,370,203.85, compared to -CNY 336,905,188.62 in the same period last year[4] - Cash inflow from investment activities was CNY 1,520,575,088.22, significantly higher than CNY 63,321,987.12 in the previous year, showing a substantial increase in investment cash flow[23] - The company reported a net cash flow from financing activities of CNY 332,276,381.40, compared to CNY 687,058,089.28 in the previous year, reflecting a decrease of about 51.6%[23] - The total operating cash inflow was CNY 1,792,072,157.04, slightly down from CNY 1,806,017,853.75 year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,996,747,169.87, reflecting a 0.14% increase from CNY 14,976,295,362.69 at the end of the previous year[5] - Total liabilities decreased to CNY 2,850,779,163.13 as of March 31, 2025, from CNY 2,865,102,076.56 at the end of 2024, a reduction of 0.5%[15] - The total assets amounted to CNY 14,383,439,650.10, a decrease from CNY 14,509,097,779.09 in the previous period[26] Research and Development - Research and development expenses for Q1 2025 totaled CNY 203,060,110.34, slightly higher than CNY 199,383,930.36 in Q1 2024, marking an increase of 1.8%[19] - Research and development expenses for Q1 2025 were CNY 98,078,477.66, a decrease of 20.7% from CNY 123,558,982.19 in Q1 2024[27] Shareholder Information - The major shareholder, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., holds 28.00% of the shares, following a change in control from Tian Shili Group[12] Inventory and Costs - The company's inventory as of March 31, 2025, was CNY 1,616,304,954.83, down from CNY 1,711,924,485.34 at the end of 2024, a decrease of 5.6%[13] - Total operating costs for Q1 2025 were CNY 1,716,567,608.85, compared to CNY 1,669,996,584.89 in Q1 2024, indicating an increase of 2.8%[18] - The company reported a decrease in the cost of sales to CNY 609,533,119.79 in Q1 2025 from CNY 536,158,811.95 in Q1 2024[27] Financial Performance - The company recognized non-recurring gains totaling CNY 78,087,713.10 during the reporting period[7] - The company reported an investment income of CNY 22,152,396.21 in Q1 2025, compared to a loss of CNY 12,402,584.70 in Q1 2024, indicating a significant turnaround[19] - The company's financial expenses showed a significant improvement, with a net income of CNY -370,490.73 in Q1 2025 compared to CNY 4,655,586.64 in Q1 2024[27] Future Outlook - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[31]